Formycon Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Formycon ha aumentado sus beneficios a una tasa media anual de 36.2%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 17.7% anual. Los ingresos han ido creciendo a una tasa media de 14.3% al año. La rentabilidad financiera de Formycon es de 15.1%, y sus márgenes netos son de 97.6%.

Información clave

36.2%

Tasa de crecimiento de los beneficios

33.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	-14.6%
Tasa de crecimiento de los ingresos	14.3%
Rentabilidad financiera	15.1%
Margen neto	97.6%
Próxima actualización de resultados	08 May 2024

Actualizaciones de resultados anteriores recientes

We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability

May 03

Recent updates

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

Nov 05

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Sep 04

Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Jul 13

Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Jun 02

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

May 23

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

Feb 01

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

Sep 25

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

May 19

Is Formycon's (ETR:FYB) 179% Share Price Increase Well Justified?

Jan 04

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Formycon. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

XTRA:FYB Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	78	76	15	9
30 Sep 23	73	17	13	12
30 Jun 23	69	-42	13	14
31 Mar 23	56	-3	13	16
31 Dec 22	42	36	12	17
30 Sep 22	38	57	11	15
30 Jun 22	34	77	10	13
31 Mar 22	35	32	8	15
31 Dec 21	37	-13	7	17
30 Sep 21	37	-15	4	23
30 Jun 21	38	-15	8	12
31 Mar 21	36	-11	9	6
31 Dec 20	34	-7	6	9
30 Sep 20	33	-4	10	0
30 Jun 20	32	-3	10	0
31 Mar 20	33	-3	10	0
31 Dec 19	33	-2	9	0
30 Sep 19	34	-2	9	0
30 Jun 19	36	-1	8	0
31 Mar 19	39	3	8	0
31 Dec 18	43	7	8	0
30 Sep 18	44	8	7	0
30 Jun 18	45	9	7	0
31 Mar 18	37	4	7	0
31 Dec 17	29	-2	6	0
30 Sep 17	24	-4	6	0
30 Jun 17	19	-6	6	0
31 Mar 17	19	-5	5	0
31 Dec 16	20	-4	5	0
30 Sep 16	18	-3	5	0
30 Jun 16	16	-2	5	0
31 Mar 16	16	-1	4	0
31 Dec 15	17	1	4	0
30 Sep 15	19	0	4	0
30 Jun 15	22	0	3	0
31 Mar 15	17	0	3	0
31 Dec 14	13	1	3	0
31 Dec 13	0	-8	3	0

Ingresos de calidad: FYB tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: Los actuales márgenes de beneficio (97.6%) de FYB son superiores a los del año pasado (84.7%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lFYB han crecido significativamente en un 36.2% al año.

Acelerando crecimiento: El crecimiento de los beneficios de FYB en el último año (110.6%) supera su media de 5 años (36.2% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de FYB en el último año (110.6%) superó al de la industria Biotechs -8.7%.

Formycon Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Recent updates

We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Price target decreased by 12% to €96.25

New minor risk - Shareholder dilution

Price target decreased by 7.9% to €103

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/S

We Think Formycon (ETR:FYB) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Formycon AG's (ETR:FYB) Share Price Not Quite Adding Up

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 146%

Price target decreased by 8.6% to €116

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Price target increased to €126

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Price target increased to €107

Consensus forecasts updated

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Consensus revenue estimates increase by 13%

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Consensus revenue estimates fall by 17%

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

Forecast breakeven date pushed back to 2023

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Price target increased to €87.00

Price target increased to €75.00

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

Price target decreased to €70.00

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020)

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Consensus forecasts updated

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Consensus forecasts updated

Full year 2020 earnings released

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

New 90-day high: €75.20

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

Is Formycon's (ETR:FYB) 179% Share Price Increase Well Justified?

Price target raised to €46.45

New 90-day high: €46.00

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

Analysts update estimates

New 90-day high: €32.00

First half earnings released

Price target raised to €36.28

New 90-day high: €28.40

Desglose de ingresos y gastos
Beta